David D. Eisenstat

8.8k total citations · 1 hit paper
105 papers, 4.9k citations indexed

About

David D. Eisenstat is a scholar working on Molecular Biology, Genetics and Neurology. According to data from OpenAlex, David D. Eisenstat has authored 105 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 39 papers in Genetics and 25 papers in Neurology. Recurrent topics in David D. Eisenstat's work include Glioma Diagnosis and Treatment (38 papers), Neuroblastoma Research and Treatments (19 papers) and Childhood Cancer Survivors' Quality of Life (9 papers). David D. Eisenstat is often cited by papers focused on Glioma Diagnosis and Treatment (38 papers), Neuroblastoma Research and Treatments (19 papers) and Childhood Cancer Survivors' Quality of Life (9 papers). David D. Eisenstat collaborates with scholars based in Canada, United States and Australia. David D. Eisenstat's co-authors include John L.R. Rubenstein, Stewart A. Anderson, Limin Shi, Magimairajan Vanan, Roger Pedersen, Alessandro Bulfone, Mengsheng Qiu, Juanito J. Meneses, Warren Mason and James Perry and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

David D. Eisenstat

101 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interneuron Migration from Basal Forebrain to Neocortex: Dependence on Dlx Genes

1997 1.2k citations David D. Eisenstat, John L.R. Rubenstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David D. Eisenstat Canada	35	2.5k	1.3k	1.3k	1.1k	609	105	4.9k
Cynthia Wetmore United States	37	2.5k 1.0×	2.6k 2.0×	1.6k 1.2×	1.1k 0.9×	294 0.5×	86	5.6k
Benjamin Deneen United States	37	2.8k 1.1×	1.3k 1.0×	1.7k 1.3×	649 0.6×	947 1.6×	86	5.5k
Jean‐Léon Thomas France	39	2.6k 1.1×	1.8k 1.4×	1.1k 0.9×	533 0.5×	606 1.0×	87	5.3k
Dies Meijer Netherlands	43	3.1k 1.2×	2.6k 2.0×	1.7k 1.3×	553 0.5×	495 0.8×	74	6.7k
Anna V. Molofsky United States	27	3.1k 1.3×	1.2k 0.9×	1.5k 1.2×	403 0.4×	626 1.0×	36	6.5k
Yonehiro Kanemura Japan	31	1.6k 0.7×	820 0.6×	695 0.5×	985 0.9×	355 0.6×	175	3.5k
Björn Scheffler Germany	30	1.4k 0.6×	746 0.6×	961 0.7×	998 0.9×	511 0.8×	82	3.4k
Takuya Shimazaki Japan	32	2.7k 1.1×	1.4k 1.1×	2.0k 1.5×	768 0.7×	466 0.8×	61	5.1k
Henrik Ahlenius Sweden	24	3.1k 1.3×	1.4k 1.1×	1.8k 1.4×	563 0.5×	318 0.5×	46	5.7k
Joel M. Levine United States	46	2.5k 1.0×	3.3k 2.5×	3.6k 2.8×	603 0.5×	868 1.4×	71	7.7k

Countries citing papers authored by David D. Eisenstat

Since Specialization

Citations

This map shows the geographic impact of David D. Eisenstat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Eisenstat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Eisenstat more than expected).

Fields of papers citing papers by David D. Eisenstat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Eisenstat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Eisenstat. The network helps show where David D. Eisenstat may publish in the future.

Co-authorship network of co-authors of David D. Eisenstat

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Eisenstat. A scholar is included among the top collaborators of David D. Eisenstat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Eisenstat. David D. Eisenstat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dodgshun, Andrew, et al.. (2025). IDH-mutant gliomas in children and adolescents - from biology to clinical trials. Frontiers in Oncology. 14. 1515538–1515538. 2 indexed citations

Ziegler, David S., et al.. (2024). A paradigm shift in how we treat pediatric low-grade glioma—Targeting the molecular drivers. Neuro-Oncology. 26(4). 593–595. 3 indexed citations

Hansford, Jordan R., Jasper de Boer, Geoffrey McCowage, et al.. (2024). “If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials. The Medical Journal of Australia. 221(10). 520–523.

Manoharan, Neevika, Marion K. Mateos, Tim Hassall, et al.. (2024). Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement. The Medical Journal of Australia. 220(10). 533–538.

Wang, Stacie Shiqi, Alexander J. Davenport, Katherine A. Watson, et al.. (2023). HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neuro-Oncology Advances. 5(1). vdad024–vdad024. 15 indexed citations

Quang, Dong Anh Khuong, Michael Sullivan, David D. Eisenstat, et al.. (2021). Growth hormone and targeted oncological agents: Are we stopping children with brain tumours from reaching their true height potential?. Journal of Paediatrics and Child Health. 57(8). 1170–1174.

Rodolico, Vito, Fan Shen, Roger Leng, et al.. (2021). PathVisio Analysis: An Application Targeting the miRNA Network Associated with the p53 Signaling Pathway in Osteosarcoma. Biocell. 45(1). 17–26. 2 indexed citations

Ghosh, Sunita, et al.. (2021). Indirect costs associated with out-of-country referral for proton therapy: a survey of adult and pediatric patients in Alberta, Canada. BMC Health Services Research. 21(1). 683–683. 3 indexed citations

Singh, Amandeep, Meghan B. Azad, Elizabeth S. Henson, et al.. (2018). The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation. PLoS ONE. 13(10). e0204792–e0204792. 22 indexed citations

10.

Le, Trung, et al.. (2017). GABAergic Interneuron Differentiation in the Basal Forebrain Is Mediated through Direct Regulation of Glutamic Acid Decarboxylase Isoforms by Dlx Homeobox Transcription Factors. Journal of Neuroscience. 37(36). 8816–8829. 46 indexed citations

11.

Johnston, Donna L., Ute Bartels, Anne‐Sophie Carret, et al.. (2017). Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). Journal of Neuro-Oncology. 133(3). 581–587. 3 indexed citations

12.

Li, Saiqun, Pierre Mattar, Rajiv Dixit, et al.. (2014). RAS/ERK Signaling Controls Proneural Genetic Programs in Cortical Development and Gliomagenesis. Journal of Neuroscience. 34(6). 2169–2190. 86 indexed citations

13.

Wigle, Jeffrey T., et al.. (2014). The role of homeobox genes in retinal development and disease. Developmental Biology. 393(2). 195–208. 46 indexed citations

14.

Reardon, David A., Burt Nabors, Warren Mason, et al.. (2014). Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. 17(3). 430–9. 134 indexed citations

15.

Easaw, Jacob C., Warren Mason, James Perry, et al.. (2011). Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme. Current Oncology. 18(3). 126–136. 81 indexed citations

16.

Perry, James, Karl Bélanger, Warren Mason, et al.. (2010). Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. Journal of Clinical Oncology. 28(12). 2051–2057. 264 indexed citations

17.

Burton, Teralee, David D. Eisenstat, & Spencer B. Gibson. (2009). BNIP3 (Bcl-2 19 kDa Interacting Protein) Acts as Transcriptional Repressor of Apoptosis-Inducing Factor Expression Preventing Cell Death in Human Malignant Gliomas. Journal of Neuroscience. 29(13). 4189–4199. 44 indexed citations

18.

Melo, Jimmy de, et al.. (2007). Dlx2 homeobox gene transcriptional regulation of Trkb neurotrophin receptor expression during mouse retinal development. Nucleic Acids Research. 36(3). 872–884. 19 indexed citations

19.

Henson, Elizabeth S., et al.. (2006). The pro-cell death Bcl-2 family member, BNIP3 is mutated in breast tumors and this mutation increases resistance to hypoxia-induced cell death in breast cancer cell lines. Cancer Research. 66. 960–960. 1 indexed citations

20.

Eisenstat, David D.. (2002). Canadian Neuro-oncology 10th Biennial Meeting. Neuro-Oncology. 4(3). 214–225.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact